The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Age Related Macular Degeneration Drug Market Research Report 2024
Synopsis
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drug market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11590 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
This report aims to provide a comprehensive presentation of the global market for Age Related Macular Degeneration Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age Related Macular Degeneration Drug.
Report Scope
The Age Related Macular Degeneration Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age Related Macular Degeneration Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age Related Macular Degeneration Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Segment by Type
Lucentis
Eylea
Avastin
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Age Related Macular Degeneration Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drug market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11590 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
This report aims to provide a comprehensive presentation of the global market for Age Related Macular Degeneration Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age Related Macular Degeneration Drug.
Report Scope
The Age Related Macular Degeneration Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age Related Macular Degeneration Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age Related Macular Degeneration Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Segment by Type
Lucentis
Eylea
Avastin
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Age Related Macular Degeneration Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Age Related Macular Degeneration Drug Market Overview
1.1 Product Overview and Scope of Age Related Macular Degeneration Drug
1.2 Age Related Macular Degeneration Drug Segment by Type
1.2.1 Global Age Related Macular Degeneration Drug Market Value Comparison by Type (2024-2030)
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Others
1.3 Age Related Macular Degeneration Drug Segment by Application
1.3.1 Global Age Related Macular Degeneration Drug Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Age Related Macular Degeneration Drug Market Size Estimates and Forecasts
1.4.1 Global Age Related Macular Degeneration Drug Revenue 2019-2030
1.4.2 Global Age Related Macular Degeneration Drug Sales 2019-2030
1.4.3 Global Age Related Macular Degeneration Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Age Related Macular Degeneration Drug Market Competition by Manufacturers
2.1 Global Age Related Macular Degeneration Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Age Related Macular Degeneration Drug Average Price by Manufacturers (2019-2024)
2.4 Global Age Related Macular Degeneration Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Age Related Macular Degeneration Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Age Related Macular Degeneration Drug, Product Type & Application
2.7 Age Related Macular Degeneration Drug Market Competitive Situation and Trends
2.7.1 Age Related Macular Degeneration Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Age Related Macular Degeneration Drug Players Market Share by Revenue
2.7.3 Global Age Related Macular Degeneration Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Age Related Macular Degeneration Drug Retrospective Market Scenario by Region
3.1 Global Age Related Macular Degeneration Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Age Related Macular Degeneration Drug Global Age Related Macular Degeneration Drug Sales by Region: 2019-2030
3.2.1 Global Age Related Macular Degeneration Drug Sales by Region: 2019-2024
3.2.2 Global Age Related Macular Degeneration Drug Sales by Region: 2025-2030
3.3 Global Age Related Macular Degeneration Drug Global Age Related Macular Degeneration Drug Revenue by Region: 2019-2030
3.3.1 Global Age Related Macular Degeneration Drug Revenue by Region: 2019-2024
3.3.2 Global Age Related Macular Degeneration Drug Revenue by Region: 2025-2030
3.4 North America Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.4.1 North America Age Related Macular Degeneration Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Age Related Macular Degeneration Drug Sales by Country (2019-2030)
3.4.3 North America Age Related Macular Degeneration Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.5.1 Europe Age Related Macular Degeneration Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Age Related Macular Degeneration Drug Sales by Country (2019-2030)
3.5.3 Europe Age Related Macular Degeneration Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Age Related Macular Degeneration Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Age Related Macular Degeneration Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Age Related Macular Degeneration Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.7.1 Latin America Age Related Macular Degeneration Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Age Related Macular Degeneration Drug Sales by Country (2019-2030)
3.7.3 Latin America Age Related Macular Degeneration Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Age Related Macular Degeneration Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Age Related Macular Degeneration Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Age Related Macular Degeneration Drug Sales by Type (2019-2030)
4.1.1 Global Age Related Macular Degeneration Drug Sales by Type (2019-2024)
4.1.2 Global Age Related Macular Degeneration Drug Sales by Type (2025-2030)
4.1.3 Global Age Related Macular Degeneration Drug Sales Market Share by Type (2019-2030)
4.2 Global Age Related Macular Degeneration Drug Revenue by Type (2019-2030)
4.2.1 Global Age Related Macular Degeneration Drug Revenue by Type (2019-2024)
4.2.2 Global Age Related Macular Degeneration Drug Revenue by Type (2025-2030)
4.2.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2019-2030)
4.3 Global Age Related Macular Degeneration Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Age Related Macular Degeneration Drug Sales by Application (2019-2030)
5.1.1 Global Age Related Macular Degeneration Drug Sales by Application (2019-2024)
5.1.2 Global Age Related Macular Degeneration Drug Sales by Application (2025-2030)
5.1.3 Global Age Related Macular Degeneration Drug Sales Market Share by Application (2019-2030)
5.2 Global Age Related Macular Degeneration Drug Revenue by Application (2019-2030)
5.2.1 Global Age Related Macular Degeneration Drug Revenue by Application (2019-2024)
5.2.2 Global Age Related Macular Degeneration Drug Revenue by Application (2025-2030)
5.2.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2019-2030)
5.3 Global Age Related Macular Degeneration Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Corporation Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Bayer HealthCare
6.2.1 Bayer HealthCare Corporation Information
6.2.2 Bayer HealthCare Description and Business Overview
6.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
6.2.5 Bayer HealthCare Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Kanghong Pharma
6.5.1 Kanghong Pharma Corporation Information
6.5.2 Kanghong Pharma Description and Business Overview
6.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
6.5.5 Kanghong Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Age Related Macular Degeneration Drug Industry Chain Analysis
7.2 Age Related Macular Degeneration Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Age Related Macular Degeneration Drug Production Mode & Process
7.4 Age Related Macular Degeneration Drug Sales and Marketing
7.4.1 Age Related Macular Degeneration Drug Sales Channels
7.4.2 Age Related Macular Degeneration Drug Distributors
7.5 Age Related Macular Degeneration Drug Customers
8 Age Related Macular Degeneration Drug Market Dynamics
8.1 Age Related Macular Degeneration Drug Industry Trends
8.2 Age Related Macular Degeneration Drug Market Drivers
8.3 Age Related Macular Degeneration Drug Market Challenges
8.4 Age Related Macular Degeneration Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
